Skip to main content

Table 4 Change in observed and predicted utility scores

From: Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis

  

Observed

Predicted

Difference

(Observed-Predicted)

Study, follow-up

n

Mean

(SD)

Mean

(SD)

R 2

Mean

(95% CI)

95% reference range

EQ-5D

      

STIVEA,

1-year

159

0.20

(0.31)

0.12 (0.24)

0.22

-0.07

(-0.12, -0.03)

-0.50 to 0.64

BROSG,

3-year

375

-0.06

(0.24)

-0.06 (0.24)

0.08

-0.00

(-0.02, 0.02)

-0.50 to 0.50

BSRBR,

6-month

749

0.08

(0.33)

0.07 (0.25)

0.19

-0.01

(-0.04, 0.01)

-0.60 to 0.63

SF-6D

      

STIVEA,

1-year

159

0.13

(0.16)

0.04 (0.07)

0.46

-0.09

(-0.11, -0.07)

-0.14 to 0.33

BROSG,

3-year

375

-0.02

(0.11)

-0.02 (0.05)

0.11

-0.00

(-0.01, 0.01)

-0.21 to 0.21

BSRBR,

6-month

749

0.05

(0.12)

0.02 (0.06)

0.33

-0.03

(-0.03, -0.02)

-0.16 to 0.21

  1. Abbreviations: BROSG = British Rheumatoid Outcome Study Group, BSRBR = British Society for Rheumatology Biologics Register, EQ-5D = EuroQol-5D, SF-6D = Short Form-6D, STIVEA = Steroids In Very Early Arthritis